Quick Takeaways
- GILEAD SCIENCES, INC. filed SCHEDULE 13G/A for Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO).
- Disclosed ownership: 20%.
- Date of event: 31 Dec 2025.
GILEAD SCIENCES, INC. - 31 Dec 2025 SCHEDULE 13G/A Report for Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO)
- Filing Manager
- GILEAD SCIENCES, INC.
- Reporting Manager
- GILEAD SCIENCES, INC.
- Symbol
- XLO
- Shares outstanding
- 72,953,156 shares
- Disclosed Ownership
- 14,517,678 shares
- Ownership
- 20%
- Form type
- SCHEDULE 13G/A
- Filing time
- 12 Feb 2026, 16:39:12 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"GILEAD SCIENCES, INC. disclosed 20% ownership in Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 14 Aug 2025.
- Current filing was accepted on 12 Feb 2026, 16:39.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 20% | 14,517,678 | 14,517,678 | 0 | /s/ Andrew D. Dickinson | Executive Vice President and Chief Financial Officer |